Cytek Biosciences, Inc.
CTKB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $200,453 | $193,015 | $164,036 | $127,950 |
| % Growth | 3.9% | 17.7% | 28.2% | – |
| Cost of Goods Sold | $89,347 | $83,589 | $63,062 | $48,806 |
| Gross Profit | $111,106 | $109,426 | $100,974 | $79,144 |
| % Margin | 55.4% | 56.7% | 61.6% | 61.9% |
| R&D Expenses | $39,402 | $44,151 | $34,858 | $24,442 |
| G&A Expenses | $43,113 | $43,972 | $34,690 | $20,835 |
| SG&A Expenses | $92,227 | $93,120 | $67,920 | $45,545 |
| Sales & Mktg Exp. | $49,114 | $49,148 | $33,230 | $24,710 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $131,629 | $137,271 | $102,778 | $69,987 |
| Operating Income | -$20,523 | -$27,845 | -$1,804 | $9,157 |
| % Margin | -10.2% | -14.4% | -1.1% | 7.2% |
| Other Income/Exp. Net | $14,823 | $12,136 | $3,064 | -$3,219 |
| Pre-Tax Income | -$5,700 | -$15,709 | $1,260 | $5,938 |
| Tax Expense | $320 | -$3,561 | -$1,224 | $2,911 |
| Net Income | -$6,020 | -$12,148 | $2,576 | $3,001 |
| % Margin | -3% | -6.3% | 1.6% | 2.3% |
| EPS | -0.046 | -0.09 | 0.019 | 0.033 |
| % Growth | 48.8% | -567.7% | -41.8% | – |
| EPS Diluted | -0.046 | -0.09 | 0.019 | 0.033 |
| Weighted Avg Shares Out | 130,611 | 135,283 | 134,511 | 133,750 |
| Weighted Avg Shares Out Dil | 130,611 | 135,283 | 138,562 | 133,750 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,360 | $6,413 | $4,619 | $49 |
| Interest Expense | $0 | $2,071 | $2,573 | $1,741 |
| Depreciation & Amortization | $10,490 | $9,230 | $5,659 | $1,242 |
| EBITDA | -$10,033 | -$4,408 | $9,492 | $8,921 |
| % Margin | -5% | -2.3% | 5.8% | 7% |